FDA Clears Tests That Allow for On-Site Therapeutic Monitori

The FDA has granted marketing authorization to Procise ADL and Procise IFX intended to measure adalimumab and infliximab levels, respectively.

Related Keywords

Larry Mimms , Drug Administration ,